

# Chronic Lower Back Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/CD7A7F8B16F2EN.html>

Date: May 2024

Pages: 130

Price: US\$ 6,499.00 (Single User License)

ID: CD7A7F8B16F2EN

## Abstracts

The 7 major chronic lower back pain markets reached a value of US\$ 6.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 10.0 Billion by 2034, exhibiting a growth rate (CAGR) of 3.7% during 2024-2034.

The chronic lower back pain market has been comprehensively analyzed in IMARC's new report titled "Chronic Lower Back Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic lower back pain is a debilitating condition characterized by persistent pain in the lower back that lasts for more than 12 weeks, despite attempts to treat or manage it. The pain can be dull, achy, or sharp and is generally accompanied by stiffness, tenderness, and muscle spasms. In many cases, the pain also radiates down the legs, causing a sensation of tingling or numbness. Additionally, chronic lower back pain can limit mobility, making it difficult to perform daily activities, such as bending, lifting, sitting for long periods, etc. Diagnosing chronic lower back pain can be complex and often requires a thorough medical evaluation by a healthcare provider. The diagnostic process typically begins with a physical exam and a medical history review. Several imaging tests, including CT scans, X-rays, MRI scans, etc., may be ordered to help identify underlying structural issues like herniated discs or spinal stenosis. Numerous blood tests and diagnostic procedures may also be performed to rule out other conditions, such as infections or autoimmune disorders.

The increasing cases of muscle or ligament strain caused by heavy lifting, sudden movements, poor posture, etc., are primarily driving the chronic lower back pain market. Apart from this, the rising prevalence of several associated risk factors, such as herniated discs, spinal stenosis, sciatica, osteoporosis, degenerative disc diseases,

etc., is also augmenting the market growth. Furthermore, the widespread adoption of massage therapies, including trigger point therapy and deep tissue massage, to help reduce muscle tension and promote relaxation is creating a positive outlook for the market. Besides this, the escalating utilization of radiofrequency ablation, which involves using heat to destroy nerve fibers that transmit pain signals from the lower back to the brain, for treating the ailment is also bolstering the market growth. Moreover, numerous pharmaceutical companies are investing in R&D activities to develop analgesics or painkillers that are more effective, economically viable, and easier to administer. This, in turn, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of non-opioid pain management techniques, such as physical therapy, acupuncture, cognitive behavioral therapy, etc., for reducing pain without the risks associated with opioid use, including addiction and withdrawal symptoms, is expected to drive the chronic lower back pain market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the chronic lower back pain market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for chronic lower back pain and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic lower back pain market in any manner.

#### Recent Developments:

In March 2024, Persica Pharmaceuticals Ltd. announced the completion of participant enrollment in its Phase 1b Modic Trial testing the efficacy of PP353 to treat chronic lower back pain.

In January 2024, Neuronoff, Inc. stated that the first-in-human Injectrode implant had been completed successfully. This milestone in chronic pain management involves two study participants receiving a minimally invasive injectable electrode that targeted peripheral nerve branches in the lumbar lower back, a critical location for new lower back pain treatments.

In December 2023, Creative Medical Technology Holdings, Inc. gained FDA approval to begin a phase 1/2 clinical trial of its revolutionary StemSpine treatment, AlloStem, to

treat chronic lower back pain. The purpose of this study is to assess the safety, effectiveness, and tolerability of CELZ-201-DDT, a unique, ready-to-use cell line produced by this company.

In August 2023, NRx Pharmaceuticals, Inc. announced that it had submitted an Investigational New Drug (IND) application to the US FDA for the use of NRX-101 to treat Chronic Pain. The IND application is based on pioneering research on the use of D-cycloserine (a major ingredient in NRX-101) in the treatment of chronic pain, as well as NRx's recent licensing of a US Patent for the use of D-cycloserine in the treatment of pain.

#### Key Highlights:

Chronic lower back pain is impacting around 1.71 billion individuals globally, with a high proportion of women.

Chronic pain appears to impact more than 20% of the European population, with a greater prevalence rate of 33-55% among patients with opioid dependence.

The prevalence of chronic lower back pain increases with age, up to 65 years.

It is predicted that 49-90% of persons in developed countries may experience lower back pain at some point in their lives.

Chronic lower back pain prevalence was 4.2% in persons aged 24 to 39 years old and 19.6% in those aged 20 to 59.

#### Drugs:

CAM2038 weekly and monthly buprenorphine injection depots are under clinical trials for the management of chronic pain in opioid-experienced patients. This drug is intended for flexible weekly and monthly dosing, allowing for treatment suited to the patient's specific needs. Because CAM2038 is designed to be delivered by healthcare professionals, it is projected to improve treatment adherence while potentially reducing the risks of diversion, misuse, overdoses, and accidental exposure to children and teenagers.

SP-103 is a pharmacologically proven medication candidate with the potential to be a best-in-class pain therapy for lower back pain. The medication has completed a Phase 2 trial in acute lower back pain and is currently preparing a Phase 2/3 trial in persistent neck pain.

AMG-0103 is under clinical development by AnGes for chronic lower back pain. It is delivered via intradiscal injection. This therapeutic candidate acts by targeting NF- $\kappa$ B (nuclear factor kappa B), a transcription factor in patients.

## Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

## Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

## Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the chronic lower back pain market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the chronic lower back pain market

Reimbursement scenario in the market

In-market and pipeline drugs

## Competitive Landscape:

This report also provides a detailed analysis of the current chronic lower back pain marketed drugs and late-stage pipeline drugs.

## In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

## Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

## Key Questions Answered in this Report:

### Market Insights

How has the chronic lower back pain market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the chronic lower back pain market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the chronic lower back pain market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of chronic lower back pain across the seven major markets?

What is the number of prevalent cases (2018-2034) of chronic lower back pain by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of chronic lower back pain by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with chronic lower back pain across the seven major markets?

What is the size of the chronic lower back pain patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of chronic lower back pain?  
What will be the growth rate of patients across the seven major markets?

Chronic Lower Back Pain: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for chronic lower back pain drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic lower back pain market?

What are the key regulatory events related to the chronic lower back pain market?

What is the structure of clinical trial landscape by status related to the chronic lower back pain market?

What is the structure of clinical trial landscape by phase related to the chronic lower back pain market?

What is the structure of clinical trial landscape by route of administration related to the chronic lower back pain market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 CHRONIC LOWER BACK PAIN - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 CHRONIC LOWER BACK PAIN - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 CHRONIC LOWER BACK PAIN - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (?2018-2034?)
  - 7.2.4 Epidemiology by Gender (?2018-2034?)
  - 7.2.5 Diagnosed Cases (?2018-2034?)
  - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (?2018-2034?)
  - 7.3.4 Epidemiology by Gender (?2018-2034?)
  - 7.3.5 Diagnosed Cases (?2018-2034?)
  - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (?2018-2034?)
  - 7.4.4 Epidemiology by Gender (?2018-2034?)
  - 7.4.5 Diagnosed Cases (?2018-2034?)
  - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (?2018-2034?)
  - 7.5.4 Epidemiology by Gender (?2018-2034?)
  - 7.5.5 Diagnosed Cases (?2018-2034?)
  - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (?2018-2034?)
  - 7.6.4 Epidemiology by Gender (?2018-2034?)
  - 7.6.5 Diagnosed Cases (?2018-2034?)
  - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (?2018-2034?)



- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (?2018-2034?)
  - 7.8.4 Epidemiology by Gender (?2018-2034?)
  - 7.8.5 Diagnosed Cases (?2018-2034?)
  - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (?2018-2034?)
  - 7.9.4 Epidemiology by Gender (?2018-2034?)
  - 7.9.5 Diagnosed Cases (?2018-2034?)
  - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

## **8 CHRONIC LOWER BACK PAIN - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 CHRONIC LOWER BACK PAIN - UNMET NEEDS**

## **10 CHRONIC LOWER BACK PAIN - KEY ENDPOINTS OF TREATMENT**

## **11 CHRONIC LOWER BACK PAIN - MARKETED PRODUCTS**

- 11.1 List of Chronic Lower Back Pain Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Drug Name – Company Name
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

## **12 CHRONIC LOWER BACK PAIN - PIPELINE DRUGS**

### 12.1 List of Chronic Lower Back Pain Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 CAM2038 - Camurus

- 12.1.1.1 Drug Overview
- 12.1.1.2 Mechanism of Action
- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status

#### 12.1.2 SP-103 - Scilex Pharmaceuticals, In

- 12.1.2.1 Drug Overview
- 12.1.2.2 Mechanism of Action
- 12.1.2.3 Clinical Trial Results
- 12.1.2.4 Safety and Efficacy
- 12.1.2.5 Regulatory Status

#### 12.1.3 AMG0103 - AnGes

- 12.1.3.1 Drug Overview
- 12.1.3.2 Mechanism of Action
- 12.1.3.3 Clinical Trial Results
- 12.1.3.4 Safety and Efficacy
- 12.1.3.5 Regulatory Status

#### 12.1.4 LY 3857210 - Eli Lilly and Company

- 12.1.4.1 Drug Overview
- 12.1.4.2 Mechanism of Action
- 12.1.4.3 Clinical Trial Results
- 12.1.4.4 Safety and Efficacy
- 12.1.4.5 Regulatory Status

#### 12.1.5 PP353 - Persica Pharmaceuticals

- 12.1.5.1 Drug Overview
- 12.1.5.2 Mechanism of Action
- 12.1.5.3 Clinical Trial Results
- 12.1.5.4 Safety and Efficacy
- 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. CHRONIC LOWER BACK PAIN - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. CHRONIC LOWER BACK PAIN – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

## **15 CHRONIC LOWER BACK PAIN - MARKET SCENARIO**

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
  - 15.2.1 Chronic Lower Back Pain - Market Size
    - 15.2.1.1 Market Size (2018-2023)
    - 15.2.1.2 Market Forecast (2024-2034)
  - 15.2.2 Chronic Lower Back Pain - Market Size by Therapies
    - 15.2.2.1 Market Size by Therapies (2018-2023)
    - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
  - 15.3.1 Chronic Lower Back Pain - Market Size
    - 15.3.1.1 Market Size (2018-2023)
    - 15.3.1.2 Market Forecast (2024-2034)
  - 15.3.2 Chronic Lower Back Pain - Market Size by Therapies
    - 15.3.2.1 Market Size by Therapies (2018-2023)
    - 15.3.2.2 Market Forecast by Therapies (2024-2034)
  - 15.3.3 Chronic Lower Back Pain - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Chronic Lower Back Pain - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Chronic Lower Back Pain - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Chronic Lower Back Pain - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Chronic Lower Back Pain - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Chronic Lower Back Pain - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)

- 15.5.2.2 Market Forecast by Therapies (2024-2034)
- 15.5.3 Chronic Lower Back Pain - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Chronic Lower Back Pain - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Chronic Lower Back Pain - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Chronic Lower Back Pain - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Chronic Lower Back Pain - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Chronic Lower Back Pain - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Chronic Lower Back Pain - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Chronic Lower Back Pain - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Chronic Lower Back Pain - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Chronic Lower Back Pain - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Chronic Lower Back Pain - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Chronic Lower Back Pain - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Chronic Lower Back Pain - Access and Reimbursement Overview

## **16 CHRONIC LOWER BACK PAIN - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 CHRONIC LOWER BACK PAIN MARKET - SWOT ANALYSIS**

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

## **18 CHRONIC LOWER BACK PAIN MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Chronic Lower Back Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/CD7A7F8B16F2EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CD7A7F8B16F2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

